PMC:7276974 / 1092-1576 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T17","span":{"begin":75,"end":80},"obj":"NCBITaxon:10239"},{"id":"T18","span":{"begin":95,"end":106},"obj":"NCBITaxon:11118"},{"id":"T19","span":{"begin":121,"end":129},"obj":"SP_7"},{"id":"T20","span":{"begin":152,"end":157},"obj":"NCBITaxon:10239"},{"id":"T21","span":{"begin":199,"end":209},"obj":"SP_7"},{"id":"T22","span":{"begin":229,"end":235},"obj":"UBERON:0001969"},{"id":"T23","span":{"begin":304,"end":315},"obj":"GO:0015671"},{"id":"T24","span":{"begin":351,"end":356},"obj":"UBERON:0000062"},{"id":"T25","span":{"begin":410,"end":415},"obj":"UBERON:0000178"},{"id":"T26","span":{"begin":454,"end":457},"obj":"GO:0071735"},{"id":"T27","span":{"begin":474,"end":483},"obj":"GO:0007565"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":229,"end":235},"obj":"Body_part"},{"id":"T6","span":{"begin":351,"end":356},"obj":"Body_part"},{"id":"T7","span":{"begin":410,"end":415},"obj":"Body_part"},{"id":"T8","span":{"begin":454,"end":457},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62874"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T3","span":{"begin":351,"end":356},"obj":"Body_part"},{"id":"T4","span":{"begin":410,"end":415},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":95,"end":119},"obj":"Disease"},{"id":"T9","span":{"begin":121,"end":129},"obj":"Disease"},{"id":"T10","span":{"begin":199,"end":207},"obj":"Disease"},{"id":"T11","span":{"begin":345,"end":364},"obj":"Disease"},{"id":"T12","span":{"begin":377,"end":395},"obj":"Disease"},{"id":"T14","span":{"begin":377,"end":385},"obj":"Disease"},{"id":"T15","span":{"begin":454,"end":468},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0000605"},{"id":"A13","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0001341"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":182,"end":190},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T17","span":{"begin":229,"end":235},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T18","span":{"begin":295,"end":303},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T19","span":{"begin":351,"end":356},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T20","span":{"begin":410,"end":415},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T21","span":{"begin":410,"end":415},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T22","span":{"begin":434,"end":437},"obj":"http://purl.obolibrary.org/obo/CL_0000990"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":70,"end":86},"obj":"Chemical"},{"id":"T4","span":{"begin":147,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":0,"end":484},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":454,"end":468},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002720"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}

{"project":"LitCovid-PubTator","denotations":[{"id":"26","span":{"begin":199,"end":209},"obj":"Species"},{"id":"31","span":{"begin":95,"end":119},"obj":"Disease"},{"id":"32","span":{"begin":121,"end":129},"obj":"Disease"},{"id":"33","span":{"begin":345,"end":364},"obj":"Disease"},{"id":"34","span":{"begin":377,"end":395},"obj":"Disease"},{"id":"35","span":{"begin":454,"end":468},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D009102"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D004342"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D017098"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 \u003c24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy."}